European HTAs And Payers On How To Tackle The Evidence Problem
Executive Summary
European payers and health technology appraisal organizations have warned that their decision making is being increasingly hampered by evidence gaps. Some solutions may lie in the better use of existing mechanisms, such as scientific advice and managed entry agreements, while others could be introduced through the overhaul of the EU pharmaceutical legislation.
You may also be interested in...
Payers Set Out Radical Wishlist For Changes To EU Pharma Legislation
European payers have called for fast-track approval pathways and only limited use of conditional approvals in the upcoming reform of the EU’s pharmaceutical legislation. They also want to see data and market protection periods reduced to boost competition.
Brazilian HTA To Adopt Cost-Effectiveness Thresholds
Brazil’s health technology assessment institute is to incorporate cost-effectiveness thresholds into its decision making.
Orphan Drug Companies Warned To Beware Of The Dutch Lock System
Companies selling orphan medicines in the Netherlands need to prepare for the likelihood that their products will enter the so-called lock system, which means they will come under extra scrutiny and take longer to reach patients.